Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients

Vascular Health and Risk Management

Volumn 2, Issue 4, 2006, Pages 433-440

  Ng, Heng Joo ^a   Lee, Lai Heng ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Bleeding; Hemophilia; Inhibitors; Recombinant activated factor VII

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIFIBRINOLYTIC AGENT; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING DISORDER; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HOME CARE; HUMAN; LOW DRUG DOSE; MUCOSAL BLEEDING; MUSCLE BLEEDING; OPTIMAL DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT DURATION;

BLOOD COAGULATION; COAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FACTOR VII; HEMOPHILIA A; HEMORRHAGE; HUMANS; RECOMBINANT PROTEINS; SURGICAL PROCEDURES, OPERATIVE; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME;

EID: 33846925118     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.4.433     Document Type: Review

References (59)

1. Abshire T, Kenet G. 2004. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost, 2:899-909.
2. Aledort LM. 2004. Comparative thrombotic event incidence after infusion of recombinant factorVIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost, 2:1700-8.
3. Allen G, Aledort L. 2006. Therapeutic decision-making in inhibitor patients. Am J Hematol, 81:71-2.
4. Arkin S, Cooper HA, Hutter JJ, et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program. Haemostasis, 1998.28:93-8.
5. Arkin S, Blei F, Fetten J, et al. 2000. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis, 11:255-9.
6. Astermark J, Ekman M, Berntorp E. 2002. Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors. Br J Haematol, 119:342-7.
7. Bech RM. 1996. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis, 26Suppl 1:135-8.
8. Berntorp E, Donfield S, Waters J, et al. 2005. The FEIBA(R) NovoSeven(R) Comparative Study (FENOC) - A Randomized Evaluation of By-Passing Agents in Hemophilia Complicated by Inhibitors. ASH Annual Meeting Abstracts, 106:324.
9. Blomback B, Carlsson K, Fatah K, et al. 1994. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res, 75:521-38.
10. Cooper HA, Jones CP, Campion E, et al. 2001. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia, 7:517-22.
11. Ehrenforth S, Krenz W, Scharrer I, et al. 1992. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet, 339:594-8.
12. Ehrlich HJ, Henzl MJ, Gomperts ED. 2002. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia, 8:83-90.
13. Hedner U. 1990. Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis, 1:307-17.
14. Hedner U. 1996. Dosing and monitoring NovoSeven treatment. Haemostasis, 26(Suppl 1):102-8.
15. Hedner U. 2006. Mechanism of action of recombinant activated factor VII: an update. Semin Hematol, 43(Suppl 1):S105-7.
16. Hedner U, Glazer S, Pingel K, et al. 1988. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet, 2:1193.
17. Hedner U, Kisiel W. 1983. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest, 71:1836-41.
18. Hilgartner M, Aledort L, Andes A, et al. 1990. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion, 30:626-30.
19. Hvid I, Rodriguez-Merchan EC. 2002. Orthopaedic surgery in haemophilic patients with inhibitors: an overview. Haemophilia, 8:288-91.
20. Ingerslev J, Freidman D, Gastineau D, et al. 1996. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis, 26Suppl 1:118-23
21. Ingerslev J, Thykjaer H, Kudsk Jensen O, et al. 1998. Home treatment with recombinant activated factor VII: results from one centre. Blood Coagul Fibrinolysis, 9Suppl 1:S107-10.
22. Kavakli K, Makris M, Zulfikar B, et al. 2006. NovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost, 95:600-5.
23. Kenet G, Lubetsky A, Gitel S, et al. 2000. Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VII. Blood Coagul Fibrinolysis, 11(Suppl 1):S35-8.
24. Kenet G, Lubetsky A, Luboshitz J, et al. 2003. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost, 1:450-5.
25. Key NS, Aledort LM, Beardsley D, et al. 1998. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost, 80:912-8.
26. Kohler M. 1999. Thrombogenicity of prothrombin complex concentrates. Thromb Res, 95(4 Suppl 1):S13-7.
27. Kreuz W, Ettingshausen CE, Zyschka A, et al. 2002. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost, 28:285-90.
28. Laurian Y, Goudemand J, Negrier C, et al. 1998. Use of recombinant activated factor VII as first line therapy for bleeding episodes in haemophiliacs with factor VIII or IX inhibitors. Blood Coagul Fibrinolysis, 9:155-156.
29. Levi M, Peters M, Bullet HR. 2005. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med, 33:883-90.
30. Lindley CM, Sawyer WT, Macik BG, et al. 1994. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther, 55:638-48.
31. Ludlam CA. 2002. The evidence behind inhibitor treatment with recombinant factor VIIa. Pathophysiol Haemost Thromb, 32Suppl 1:13-8.
32. Ludlam CA, Smith MP, Morfini M, et al. 2003. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol, 120:808-13.
33. Lusher JM. 1998. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl, 63:7-10.
34. Lusher JM. 2000. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis, 11(Suppl 1):S45-9.
35. Lusher JM. 2002. First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Semin Thromb Hemost, 28:273-6.
36. Lusher JM, Roberts HR, Davignon G, et al. 1998. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors, rFVIIa Study Group. Haemophilia, 4:790-8.
37. Mauser-Bunschoten EP, de Goede-Bolder A, Wielenga JJ, et al. 1998. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium. Neth J Med, 53:249-55.
38. Mauser-Bunschoten EP, Koopman MM, Goede-Bolder AD, et al. 2002. Recombinant Factor VIIa Data Collection Group. Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors. Haemophilia, 8:649-56.
39. Mayer SA, Brun NC, Begtrup K, et al. 2005. Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med, 352:777-85.
40. Montoro JB, Altisent C, Pico M, et al. 1998. Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor. Haemophilia, 4:762-5.
41. Munro FL, Jones HW. 1943. The detrimental effect of frequent transfusions in the treatment of a patient with hemophilia. Am J M Sc, 206:107.
42. Negrier C, Goudemand J, Sultan Y, et al. 1997. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost, 77:1113-9.
43. Ng HJ, Lob SM, Tan DC, et al. 2004. Thrombosis associated with the use of recombinant activated factor VII:profiling two events. Thromb Haemost, 92:1448-9.
44. Nicolaisen EM. 1998. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis, 9(Suppl 1):S119-23.
45. O'Connell KA, Wood JJ, Wise RP, et al. 2006. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA, 295:293-8.
46. Parameswaran R, Shapiro AD, Gill JC, et al. 2005. HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia, 11:100-6.
47. Rice KM, Savidge GF. 1996. NovoSeven (recombinant factor VIIa) in central nervous systems bleeds. Haemostasis, 26(Suppl 1):131-4.
48. Rodriguez-Merchan EC, Rocino A, Ewenstein B, et al. Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia, 2004.10 Suppl 2:50-2.
49. Santagostino E, Gringeri A, Mannucci PM. 1999. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol, 104:22-6.
50. Santagostino E, Mancuso ME, Rocino A, et al. 2006. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost, 4:367-71.
51. Scharrer I. 1999. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia, 5:253-9.
52. Scharrer I, Bray GL, Neutzling O. 1999. Incidence of inhibitors in haemophilia A patients a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia, 5:145-54.
53. Schulman S, Bech Jensen M, et al. 1996. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost, 75:432-6.
54. Shapiro AD, Gilchrist GS, Hoots WK, et al. 1998. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost, 80:773-8.
55. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, et al. 1981. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med, 305:717-21.
56. Smith MP, Ludlam CA, Collins PW, et al. 2001. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost, 86:949-53.
57. Villar A, Aronis S, Morfini M, et al. 2004. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia, 10:352-9.
58. von Depka M. 2005. Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety. Haemophilia, 11(Suppl 1):18-23.
59. Warrier I, Lusher JM. 1998. Development of anaphylactic shock in haemophilia B patients with inhibitors. Blood Coagul Fibrinolysis, 9(Suppl 1):S125-8.